Type 2 diabetes is a metabolic, chronic disorder characterized by insulin resistance and
elevated blood glucose levels. Although a large drug portfolio exists to keep the blood …

Despite the successful development of new therapies for the treatment of type 2 diabetes,
such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose …

Type 2 diabetes mellitus (T2DM) is one of the greatest health crises of our time and its
prevalence is projected to increase by> 50% globally by 2045. Currently, 10 classes of …

Background Weight loss is often key in the management of obese or overweight patients
with type 2 diabetes, yet few treatments for diabetes achieve clinically meaningful weight …

Background The prevalence of non-alcoholic fatty liver disease (NAFLD) has been
increasing rapidly. It is nowadays recognized as the most frequent liver disease, affecting a …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists are established pharmaceutical
therapies for the treatment of type 2 diabetes and obesity. They mimic the action of GLP-1 to …

Hundred years after the discovery of glucagon, its biology remains enigmatic. Accurate
measurement of glucagon has been essential for uncovering its pathological hypersecretion …

Although it is well-established that reductions in the ratio of insulin to glucagon in the portal
vein have a major role in the dysregulation of hepatic glucose metabolism in type-2 …

Glucagon is secreted from the pancreatic alpha cells upon hypoglycemia and stimulates
hepatic glucose production. Type 2 diabetes is associated with dysregulated glucagon …

There is a wide variety of kinds of lipids, and complex structures which determine the
diversity and complexity of their functions. With the basic characteristic of water insolubility …